Custom Services order now ship next day

Antibody-drug Conjugates Production

As an industry leading expert in antibody engineering and bio-pharmaceuticals, Creative Biolabs is committed to developing new generation of pharmaceuticals against various diseases for both scientific and clinical purposes. Antibody-drug conjugates (ADCs) are a class of novel APIs with high potency. Our experienced scientists and technicians can provide comprehensive custom services to develop numerous ADC products for every stage of development, from antibody expression to cGMP manufacturing.

Antibody-drug conjugates productionFigure: Mechanism of action of ADCs (Nat Rev Drug Discov. 2006)

ADCs are composed of antibodies and cytotoxic drugs, conjugated by chemical linkers. They combine the abilities of mAbs and cytotoxic drugs, improving the control of drug pharmacokinetics and allowing specific drug delivery to target cells. A number of ADCs have been researched and entered clinical trials in recent years. And the successful FDA approval of brentuximab vedotin (Adcetris®, SGN-35) and ado-trastuzumab emtansine (Kadcyla®, T-DM1) further suggests that ADCs are promising therapeutic agents for oncotherapy. Our scientists from different disciplines, such as biochemical and chemistry, work together to design and perform optimized processes in ADC development.

Based on the proprietary ADC platform, Creative Biolabs provides a series of products and services:


  1. Schrama D, et al. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov. 2006 Feb; 5(2):147-59.

For research use only. Not intended for any clinical use.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
    Go to compare

    Go to compare